CLAIMS

1. A liquid depot for sustained release of an active agent in the eye, the liquid depot comprising: a tocopherol; an ocular film-forming excipient; and an active agent; wherein the liquid depot has a viscosity of about 850 cP to about 1100 cP, inclusive.

2. The liquid depot of claim 1, wherein the tocopherol is α-, β-, γ- or δ-tocopherol, or α-, β-, γ- or δ-tocotrienol.

3. The liquid depot of any one of claims 1-2, wherein the tocopherol is an α-, β-, γ-, or δ-tocopherol.

4. The liquid depot of any one of claims 1-3, wherein the tocopherol is tocopheryl acetate.

5. The liquid depot of any one of claims 1-4, wherein the ocular film-forming excipient consists of medium-chain triglycerides.

6. The liquid depot of any one of claims 1-5, wherein the active agent is a corticosteroid.

7. The liquid depot of claim 6, wherein the corticosteroid is a member selected from the group consisting of dexamethasone, prednisolone, prednisone, loteprednol, triamcinolone and fluorometholone.

8. The liquid depot of claim 7, wherein the liquid depot comprises (a) about 10% dexamethasone; and (b) about 90% of a mixture of tocopheryl acetate:medium-chain triglycerides at a ratio of about 90:10 to about 60:40.

9. The liquid depot of claim 5, wherein the liquid depot comprises, on a wt% basis, (a) about 10% prednisolone and (b) about 90% of a mixture of tocopheryl acetate:medium-chain triglycerides at wt/wt a ratio of about 80:20.

10. The liquid depot of claim 7, wherein the liquid depot comprises, on a wt% basis, (a) about 10% loteprednol and (b) about 90% of a mixture of tocopheryl acetate:medium-chain triglycerides at wt/wt a ratio of about 80:20.

11. The liquid depot of any one of claims 1-5, wherein the active agent is an anti-infective.

12. The liquid depot of any one of claims 1-7 further comprising an anti-infective.

13. The liquid depot of claim 11 or 12, wherein the anti-infective is moxifloxacin.

14. The liquid depot of claim 12, wherein the liquid depot comprises (a) about 10%-20% moxifloxacin; and (b) about 80%-90% of a mixture of tocopheryl acetate:medium-chain triglycerides at a ratio of about 70:30.

15. The liquid depot of claim 12, wherein the liquid depot comprises, on a wt% basis (a) about 15% ciprofloxacin; and (b) about 85% of a mixture of tocopheryl acetate:medium-chain triglycerides at a ratio of about 70:30.

16. The liquid depot of claim 12, wherein the liquid depot comprises, on a wt% basis (a) about 10% gatifloxacin; and (b) about 90% of a mixture of tocopheryl acetate:medium-chain triglycerides at a ratio of about 70:30.

17. The liquid depot of any one claim claims 1-6, comprising dexamethasone and moxifloxacin in a mixture of tocopheryl acetate:medium-chain triglycerides at a ratio of about 90:10 to about 60:40.

18. The liquid depot of any one of the preceding claims, wherein the liquid depot is disposed within a single-use dispenser.

19. A kit comprising at least one single-use dispenser, wherein the at least single-use dispenser comprises the liquid depot of any one of claims 1-18.

20. A method of treating a malady of the eye in a subject in need thereof, comprising topically administering to the eye of the subject a liquid depot comprising (a) at least one active agent; and (b) a mixture of mixture of tocopheryl acetate:medium-chain triglycerides at a weight ratio of about 90:10 to about 60:40.

21. The method of claim 20, wherein the medium-chain triglycerides is at least one MIGLYOL® neutral oil.

22. The method of claim 20 or 21, wherein the malady of the eye is inflammation, infection, allergic reaction, or glaucoma.

23. The method of claim 20 or 21, wherein the malady of the eye is infection, corneal abrasion or other trauma to the eye surface, blepharitis, inflammatory meibomian gland disease, meibomian gland dysfunction, allergic conjunctivitis, chronic conjunctivitis, Sjögren's syndrome, dry eye (keratoconjunctivitis sicca), aqueous-deficient dry eye, mucin-deficient dry eye (punctate epithelial keratitis), episcleritis, keratitis (corneal ulcers), pterigia, Stevens-Johnson syndrome, ocular citatrical pemphigoid/mucous membrane pemphigoid, irregular cornea condition or other surface abnormalities, epitheliopathy, neurotrophic cornea, corneal dystrophy such as Fuch's dystrophy, peripheral or marginal degeneration of the cornea, conjunctivochalasis, glaucoma, conjunctival degeneration such as pinguecula, or pingueculitis.

24. The method of any one of claims 20-21, wherein said administering is intermittent.

25. The method of claim 24, wherein said intermittent administration is for at least about 24 hours, 48 hours, 72 hours (3 days), 4 days, 5 days, 6 days, 7 days (1 week), 14 days (2 weeks), or 21 days (3 weeks).

26. The method of claim 24, wherein said intermittent administration is for at least about 24 hours.

27. A liquid depot comprising: a tocopherol; an ocular film-forming excipient; and, optionally, an active agent;

wherein the liquid depot has a viscosity of about 850 cP to about 1100 cP, inclusive.

28. The liquid depot of claim of claim 27, consisting of a tocopherol; an ocular film-forming excipient, wherein the ocular film-forming excipient is a triglyceride or mixture of triglycerides.

29. The liquid depot of claim of claim 27, wherein the ocular film-forming excipient is MIGLYOL® decanoyl/octanoyl glycerides.

30. The liquid depot of any one of claims 27-30, wherein the tocopherol is tocopheryl acetate.

31. The liquid depot of any one of claims 27-30, wherein the weight ratio of tocopherol to film-forming agent is in a range of about 60:40 to about 90:10.

32. A method of providing a protective coating to the eye, comprising the step of instilling into the eye the liquid depot of any one of claims 26-30.

33. The method of claim 32, further comprising intermittently repeating the instilling step.